生技仿製藥：歐洲的保險用戶 (Payer) 展望 (2016年)
Biosimilars: European Payer Perspectives (2016)
|生技仿製藥：歐洲的保險用戶 (Payer) 展望 (2016年) Biosimilars: European Payer Perspectives (2016)|
|出版日期: 2016年01月01日||內容資訊: 英文||
The European market for biosimilars has seen a year of progress and change , with more therapies available and changing attitudes from many payers . Driven by the pressing need to control drug costs, payers have notably moved their position in key areas such as interchangeabilty and indication extrapolation. But where are the sticking points? What are the critical factors for success? What more could the biosimilar industry do to help its cause?
This report identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Biosimilars: European Payer Perspectives is informed with candid insights of 15 European payers from the five leading European markets and packed with actionable information. It is essential reading for all commercial and research planners in branded and biosimilar manufacturers .
"The key reimbursement challenge at the moment comes down to the four-letter word of cost: every healthcare organisation is really struggling to contain cost."
For this report FirstWord has interviewed 15 payers, 3 from each EU5 country. Payers interviewed have direct experience of assessing biosimilars for inclusion on formulary, either as part of a committee or as the lead decision-maker.